FIRALIS GROUP AFFILIATES
Together, bridging science to clinics
Since its creation in 2008, Firalis initiated and coordinated, also participated in many collaborative research projects, particularly funded by the European Commission grants and established a contractual network with European academia, including university hospitals, clinical centers of excellence and biobanks of interest.
Starting from 2012, this network is strengthened with technology investments and several acquisitons with a particular focus on complementary know-how and IP. Acquisition of FIRALIS MOLECULAR PRECISION S.A. (formerly Tc Land Expression) in July 2013 is realized concurrently with a fundraising from a consortium including Auriga Partners VC, then by early 2014, Firalis acquired assets of another biotech with important patents in the field of Neurodegenerative disorders, on which grounds AMONETA DIAGNOSTICS S.A.S. is founded. Thanks to its IP portfolio and with Firalis administrative support behind it, Amoneta received before long, a first grant from EuroTransBio for a pre-clinical study to develop a multiplex biomarker test. Then in April 2015, with an excellent evaluation report, Amoneta succeeded to raise 5 Mio € of grant from the EC Program “Horizon 2020”, for its clinical study ADDIA, to qualify in clinics the outcome of ADKIT program; finally 2 Mio $ from Alzheimer's Drug Discovery Foundation (ADDF) bringing together several philantrophists including the Bill Gates Foundation.
Following creation of LODIAG S.A.S. (check out Lodiag's website here); Firalis Group continues considering M&A opportunities, to internalize complementary technologies and know-how, for a much faster commercialization of innovative, high value-added in-vitro diagnostic tools.
Firalis constantly extends the range of its biomarker projects and product pipelines,
while developing and commercializing first-in-market IVD tools.